Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects

Background  Recombinant (rec-) coagulation factor VIII concentrates available for hemophilia A (HA) treatment differ in cell line production and structure, which could affect their pharmacodynamics and immunogenicity. Clinical trials showed that previously untreated patients with severe HA present h...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:TH Open
Autors principals: De Cristofaro, Raimondo, Sacco, Monica, Lancellotti, Stefano, Berruti, Federico, Garagiola, Isabella, Valsecchi, Carla, Basso, Maria, Di Stasio, Enrico, Peyvandi, Flora
Format: Artigo
Idioma:Inglês
Publicat: Georg Thieme Verlag KG 2019
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6524925/
https://ncbi.nlm.nih.gov/pubmed/31249992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/s-0039-1688413
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars